ArticleBMC health services research2026
Who benefits more from an improved social health insurance? Evidence from supplementary high-cost illness insurance in China.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChina introduced the Supplementary High-Cost Illness Insurance (SHCII) to strengthen financial protection against medical impoverishment. This study assesses its effectiveness and, critically, examines the distribution of its benefits across population subgroups to identify who benefits more.
methodsWe used 2013 and 2018 survey data from Shandong Province and a difference‑in‑differences design, restricting the sample to hospitalized patients (n = 3,136). The treatment group comprised patients whose out‑of‑pocket expenses exceeded city‑specific 2018 SHCII thresholds; the control group comprised those below the thresholds. The outcome was Vulnerability to Expected Poverty (VEP). Subgroup analyses were performed by income, urban‑rural residence, healthcare access, and age.
resultsPatients who benefit from SHCII experienced a significant reduction in VEP relative to those below the threshold (OR = 0.624; average marginal effect = -0.064). The protective effect was statistically significant for low‑income individuals, rural residents, those with healthcare access within 15 min, and adults aged 45 years and above. No significant effect was found for urban residents or for those with poorer geographical access to care.
conclusionPatients who benefit from SHCII experienced a greater reduction in poverty vulnerability relative to those below the threshold, with effects concentrated among low‑income, rural, older, and well‑accessed populations. No significant association was observed for urban residents. The findings from Shandong, where policy parameters are broadly consistent with national guidelines, are likely generalizable to other provinces with similar policy designs and rural healthcare infrastructure. Future research is needed to test how different policy parameters affect the results. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.